Real-World Data Shows Long-Term Stability for Leqembi Patients
New data from the LEADER study, presented at the 2026 Alzheimer’s Association International Conference, reveals that nearly 83% of patients with early-stage Alzheimer’s disease remained stable or showed improvement after an average of 17 months of treatment with Leqembi, providing critical evidence of the drug's effectiveness outside of controlled clinical trials.

























